$1.69
—
USD · final close, as of 2026-07-02 · marketstack
Delisted — deregistered 2026-07-01
Clinical trials
catalyst calendar across sponsors →Studies where APTOF is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 with posted results
Held by 0 tracked-famous managers · FINRA short interest 2.0 days to cover (settled 2026-06-30) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT03850574Frequency and severity of drug-related adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion | Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia | 240 | Nov 2026 | ≤ 103 d | 2025-08-26 |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasNCT03893682Incidence of treatment-emergent adverse events of CG-806Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Change in corporate strategy | Drug: CG-806 | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma | 36 | 2024-05-17actual | — | 2025-03-07 |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSNCT04477291Incidence of treatment-emergent adverse events of CG-806Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Change in corporate strategy | Drug: CG-806 | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 45 | 2024-04-15actual | — | 2025-03-07 |
| A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSNCT02267863Incidence of treatment-emergent adverse events of APTO-253Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Drug manufacturing process and procedure review | Drug: APTO-253 | Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult, Acute Myelogenous Leukemia, High Risk Myelodysplasia | 21 | Sep 2021actual | — | 2022-08-22 |
| A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid TumoursNCT01281592To determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.Open-label · Treatment | Phase 1 | Completed | Drug: LOR-253 HCl | Advanced or Metastatic Solid Tumours | 36 | Jul 2013actual | — | 2014-02-25 |
| Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)NCT00565058results2015-07-27Overall Response Rate of GTI-2040 Combined With HiDAC in Refractory or Relapsed AMLRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: GTI-2040 | Acute Myeloid Leukemia | 27 | Sep 2009actual | — | 2015-07-27 |
| A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic CancerNCT00040092Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Virulizin® | Pancreatic Cancer | 400 | Jul 2005actual | — | 2008-01-07 |
| Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell CarcinomaNCT00056173Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: GTI-2040 | Carcinoma, Renal Cell, Metastases, Neoplasm | 43 | Dec 2004actual | — | 2008-01-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19